modelLatanoprost
Extends from Pharmacolibrary.Drugs.ATC.S.S01EE01.
Information
| name: | Latanoprost | |
| ATC code: | S01EE01 | route: | ophthalmic |
| compartments: | 1 | |
| dosage: | 0.05 | mg |
| volume of distribution: | 0.16 | L |
| clearance: | 0.4 | L/h/kg |
| other parameters in model implementation | ||
Latanoprost is a prostaglandin F2α analogue used primarily for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is an ophthalmic solution administered as one drop in the affected eye(s) once daily. It is widely approved and used in clinical practice.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers after topical ocular administration.
References
Digiuni, M, et al., & Rossetti, L (2013). An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension. Journal of glaucoma 22(9) 707–712. DOI:10.1097/IJG.0b013e318259b47c PUBMED:https://pubmed.ncbi.nlm.nih.gov/22595934
Lallemand, F, et al., & Garrigue, JS (2012). Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. Journal of drug delivery 2012 604204–None. DOI:10.1155/2012/604204 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22506123
Hariharan, S, et al., & Mitra, AK (2009). Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 25(6) 487–498. DOI:10.1089/jop.2009.0049 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20028257
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)